Shuttle Pharmaceuticals Files S-1

Ticker: SHPH · Form: S-1 · Filed: Sep 20, 2024 · CIK: 1757499

Shuttle Pharmaceuticals Holdings, Inc. S-1 Filing Summary
FieldDetail
CompanyShuttle Pharmaceuticals Holdings, Inc. (SHPH)
Form TypeS-1
Filed DateSep 20, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001, $0.125, $0, $0.001
Sentimentneutral

Sentiment: neutral

Topics: s-1, pharmaceuticals, sec-filing

TL;DR

Shuttle Pharma filed its S-1 on 9/20/24, check financials for Q2 2024.

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 form on September 20, 2024, detailing its business operations and financial status. The company, located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879, is in the pharmaceutical preparations industry. The filing provides financial data for periods ending June 30, 2024, and December 31, 2023, including information on related and non-related party transactions.

Why It Matters

This S-1 filing provides crucial insights into Shuttle Pharmaceuticals' financial health and business strategy, which is essential for investors and stakeholders to assess the company's future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, it indicates a potential offering or significant corporate event, which inherently carries market and regulatory risks.

Key Numbers

  • 2024-06-30 — Financial Period End (Key date for financial data presented in the filing.)
  • 2023-12-31 — Financial Period End (Key date for financial data presented in the filing.)

Key Players & Entities

  • Shuttle Pharmaceuticals Holdings, Inc. (company) — Filer of the S-1 document.
  • 401 Professional Drive, Suite 260, Gaithersburg, MD 20879 (location) — Company's business and mailing address.
  • September 20, 2024 (date) — Date of the S-1 filing.
  • 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations.

FAQ

What is the primary purpose of this S-1 filing for Shuttle Pharmaceuticals Holdings, Inc.?

The S-1 filing is typically used for companies planning to offer securities to the public, indicating potential fundraising or stock market listing activities.

What industry does Shuttle Pharmaceuticals Holdings, Inc. operate in?

Shuttle Pharmaceuticals Holdings, Inc. operates in the Pharmaceutical Preparations industry, classified under SIC code 2834.

What are the key financial reporting periods covered by this filing?

The filing provides financial data for periods ending on June 30, 2024, December 31, 2023, and December 31, 2022.

Where is Shuttle Pharmaceuticals Holdings, Inc. located?

The company's business and mailing address is 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.

When was this S-1 filing submitted to the SEC?

This S-1 filing was submitted to the SEC on September 20, 2024.

Filing Stats: 4,564 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2024-09-20 06:04:08

Key Financial Figures

  • $0.00001 — he "Shares") of common stock, par value $0.00001 per share ("common stock"), or Pre-Fund
  • $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
  • $0 — ice of per share of common stock, minus $0.001, and the remaining exercise price o
  • $0.001 — e of each Pre-Funded Warrant will equal $0.001 per share. The Pre-Funded Warrants will

Filing Documents

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 62 MANAGEMENT 74 EXECUTIVE AND DIRECTOR COMPENSATION 83 BENEFICIAL OWNERSHIP OF SECURITIES 86 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 87 CAPITALIZATION 88

DILUTION

DILUTION 89 DIVIDEND POLICY 9 0 DESCRIPTION OF CAPITAL STOCK 90 DESCRIPTION OF SECURITIES WE ARE OFFERING 95 PLAN OF DISTRIBUTION 97 LEGAL MATTERS 99 EXPERTS 99 WHERE YOU CAN FIND MORE INFORMATION 99 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part and which we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the heading "Where You Can Find More Information" before making your investment decision. You should rely only on the information provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copi

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.